Replies to post #1483 on Biotech Values

[DewDiligence]

Re: Pro-Pharmaceuticals:

[I wonder how much DD the new director did before signing on. The timing sure isn’t fortuitous.]

http://biz.yahoo.com/bw/040312/125418_1.html

>>
Pro-Pharmaceuticals Appoints Jerald K. Rome to Board of Directors

Friday March 12, 2:21 pm ET

NEWTON, Mass.--(BUSINESS WIRE)--March 12, 2004--Pro-Pharmaceuticals, Inc. (Amex: PRW - News), a developer of novel cancer therapeutics to target cancer cells through carbohydrate chemistry, today announced the appointment of Jerald K. Rome to its Board of Directors. Mr. Rome, former Chairman, President and CEO of Moore Medical Corporation, an Amex-listed distributor of national brand pharmaceuticals; a Founder and President of Amberline Pharmaceutical Care Company, a marketer of private label and non-prescription pharmaceuticals, and Vice President and a Director of the National Association of Pharmaceutical Manufacturers.

"We are pleased that Jerry has accepted our invitation to join the Board," said David Platt, Chairman, President & CEO, Pro-Pharmaceuticals, Inc. "His experience and expertise will be invaluable as we advance our cancer therapeutic compounds through clinical trials."

"Pro-Pharmaceuticals has made great strides advancing its drug development program, in particular with the initiation of a Phase II clinical study of its lead carbohydrate compound DAVANAT® with 5-Fluorourcil (5-FU) in refractory colorectal cancer patients," said Mr. Rome. "I look forward to working with the Company through its next phase of growth; bringing cancer therapeutics to market."
<<